X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Tilda Sciences gain two medicines, Daraprim (pyrimethamine), approved for treatment of toxoplasmosis and Vecamyl (mecamylamine HCI), approved for management of hypertension, from Vyera Pharmaceuticals.
Lead Product(s): Pyrimethamine
Therapeutic Area: Infections and Infectious Diseases Product Name: Daraprim
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Tilde Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition December 07, 2023
Details:
Through the agreement, Phoenixus gains access to Daraprim, a prescription medication that contains pyrimethamine for the treatment of toxoplasmosis and Vecamyl (mecamylamine HCI), indicated for the management of moderately severe to severe essential hypertension.
Lead Product(s): Pyrimethamine
Therapeutic Area: Infections and Infectious Diseases Product Name: Daraprim
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Phoenixus
Deal Size: $0.6 million Upfront Cash: Undisclosed
Deal Type: Agreement August 01, 2023
Details:
Under this amendment, for additional cash payments, Seelos has agreed to repurchase 9% of the future royalties and reduce its royalty obligations to a mid-single digit percentage on any future net sales of SLS-002.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: SLS-002
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Seelos Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 18, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
